Choiniere Roselyne, Al Qa'qa' Shifaa', Cheung Carol C, Finelli Antonio, Prendeville Susan
Division of Anatomic Pathology, Laboratory Medicine Program, University Health Network, Toronto, Ontario, Canada.
Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
J Clin Pathol. 2024 Jul 20. doi: 10.1136/jcp-2024-209711.
Low-grade oncocytic tumour (LOT) and eosinophilic vacuolated tumour (EVT) are recently described emerging entities, which demonstrate distinct features but are not yet recognised as separate neoplasms in the fifth WHO classification. Published series to date have been largely multi-institutional and based on surgically resected tumours. This study aims to determine the frequency, clinicopathologic features and outcome of LOT and EVT in a single institutional series of oncocytic/eosinophilic renal neoplasms, including patients managed with active surveillance and non-surgical intervention.
Cases were identified from a consecutive institutional series of in-house renal tumours diagnosed on biopsy and/or nephrectomy (2003-2023). Tumours with a diagnosis or differential diagnosis of oncocytoma, chromophobe renal cell carcinoma or oncocytic neoplasm not otherwise specified (including LOT, EVT and tumours with overlapping hybrid features) were retrospectively reviewed and classified/reclassified.In total, 605 oncocytic/eosinophilic renal neoplasms were reviewed, among which 33 LOT (5.5%) and 5 EVT (0.8%) were identified. LOT were CK7+, CD117- and GATA3+ (94%). EVT were CD117+, CK7 focal+ (80%) and cathepsin K+ (80%). At the median follow-up of 34 months (range 2-253) and 56 months (range 8-90) for LOT and EVT, respectively, there was no evidence of recurrence following ablation/surgical resection, metastasis or death from disease for all patients, including the 22 managed with active surveillance (20 LOT and 2 EVT).
LOT and EVT comprised a minority of oncocytic renal neoplasms in this series. We report a large institutional series including patients managed non-surgically, with no adverse outcome, adding to the existing literature indicating a benign outcome.
低度嗜酸性细胞瘤(LOT)和嗜酸性空泡状肿瘤(EVT)是最近描述的新出现的实体,它们表现出不同的特征,但在世界卫生组织第五版分类中尚未被确认为独立的肿瘤。迄今为止发表的系列研究大多是多机构的,且基于手术切除的肿瘤。本研究旨在确定在一个单一机构的嗜酸性/嗜酸性肾肿瘤系列中LOT和EVT的发生率、临床病理特征及预后,包括接受主动监测和非手术干预的患者。
从2003年至2023年连续的机构内部经活检和/或肾切除术诊断的肾肿瘤系列中识别病例。对诊断或鉴别诊断为嗜酸细胞瘤、嫌色肾细胞癌或未另行指定的嗜酸性肿瘤(包括LOT、EVT和具有重叠混合特征的肿瘤)的肿瘤进行回顾性审查并分类/重新分类。
总共审查了605例嗜酸性/嗜酸性肾肿瘤,其中33例LOT(5.5%)和5例EVT(0.8%)被识别。LOT呈CK7阳性、CD117阴性和GATA3阳性(94%)。EVT呈CD117阳性、CK7局灶性阳性(80%)和组织蛋白酶K阳性(80%)。LOT和EVT的中位随访时间分别为34个月(范围2 - 253个月)和56个月(范围8 - 90个月),所有患者,包括22例接受主动监测的患者(20例LOT和2例EVT),均无消融/手术切除后复发、转移或疾病死亡的证据。
在本系列中,LOT和EVT占嗜酸性肾肿瘤的少数。我们报告了一个大型机构系列,包括接受非手术治疗的患者,且无不良预后,这为现有表明良性预后的文献增添了内容。